Related Experiment Video

Updated: Aug 8, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Androgen receptors in prostate cancer

Z Culig1, H Klocker, G Bartsch

  • 1Department of Urology, University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. zoran.culig@uibk.ac.at

Endocrine-Related Cancer
|September 19, 2002
PubMed

Insights

Prostate cancer treatment targets the androgen receptor (AR). Studies show AR can become resistant to therapy, driving cancer growth and necessitating new therapeutic strategies to inhibit AR expression and function.

Area of Science:

  • Molecular Biology
  • Oncology
  • Endocrinology

Background:

  • Prostate cancer is a leading malignancy in men, frequently expressing the androgen receptor (AR).
  • Current treatments aim to reduce androgen levels or block AR function.
  • AR plays a critical role in prostate cancer progression and treatment resistance.

Purpose of the Study:

  • To investigate androgen receptor (AR) function and resistance mechanisms in prostate cancer cells under endocrine therapy.
  • To identify potential therapeutic targets and agents for inhibiting AR expression and overcoming treatment resistance.

Main Methods:

  • Studied AR function in LNCaP prostate cancer cells undergoing long-term steroid depletion.
  • Analyzed AR expression, activity, and apoptosis resistance in generated sublines.
  • Examined the effects of chemopreventive agents and AR antisense oligonucleotides on AR expression.

Main Results:

  • Prostate cancer cells developed resistance to androgen deprivation therapy, showing increased AR expression and activity.
  • Mutations in AR can lead to activation by alternative ligands, contributing to metastatic disease.
  • AR can be activated by growth factors and other signaling molecules in the absence of androgens.

Conclusions:

  • Androgen receptor (AR) dysregulation and resistance are key challenges in advanced prostate cancer.
  • Emerging therapies focus on down-regulating AR expression and overcoming antiandrogen resistance.
  • Identifying novel agents and strategies to inhibit AR signaling is crucial for improving patient outcomes.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...